Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Trial of Quabodepistat-containing Regimens for Rifampicin-resistant/Multidrug-resistant Pulmonary Tuberculosis
jRCT2031260045Phase 3Recruiting
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Jun 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of quabodepistat in pulmonary tuberculosis (TB) and Tuberculosis (TB) (4 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoints: Unfavorable outcome proportion and Grade ≥3 TEAEs, SAEs, or AEs leading to dose modification. Started Jun 2026; status: recruiting.
02
Drugs
quabodepistat
03
Conditions
pulmonary tuberculosis (TB)Tuberculosis (TB)
Beyond the preview
Go deeper on jRCT2031260045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260045.